The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities

Trends in Biotechnology

Volumn 25, Issue 7, 2007, Pages 289-298

  Yun, Chul Ho ^a   Kim, Keon Hee ^a   Kim, Dong Hyun ^a   Jung, Heung Chae ^b   Pan, Jae Gu ^b  

^a Chonnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCATALYSTS; BIOSYNTHESIS; CATALYST ACTIVITY; ENZYMES; METABOLITES; POLYPEPTIDES;

CATALYTIC DIVERSITY; DRUG DISCOVERY; MONOOXYGENASE SYSTEMS;

BACTERIA;

BACTERIAL PROTEIN; BUSPIRONE; CYTOCHROME P450; CYTOCHROME P450 BM3; DRUG METABOLIZING ENZYME; PROPRANOLOL; TESTOSTERONE;

ARTICLE; BACILLUS MEGATERIUM; BIOCATALYST; CATALYSIS; DRUG DETERMINATION; DRUG SYNTHESIS; ENZYME SUBSTRATE; OXIDATION; OXYGENATION; PHARMACEUTICS; PRIORITY JOURNAL; PROKARYOTE;

BACILLUS MEGATERIUM; BACTERIAL PROTEINS; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; EVOLUTION, MOLECULAR; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS;

BACILLUS MEGATERIUM; BACTERIA (MICROORGANISMS); MAMMALIA; PROKARYOTA;

EID: 34250215649     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2007.05.003     Document Type: Article

References (54)

1. Bernhardt R. Cytochromes P450 as versatile biocatalysts. J. Biotechnol. 124 (2006) 128-145
2. Guengerich F.P. Cytochrome P450 enzymes in the generation of commercial products. Nat. Rev. Drug Discov. 1 (2002) 359-366
3. Kubo T., et al. Enantioselective epoxidation of terminal alkenes to (R)- and (S)-epoxides by engineered cytochromes P450 BM-3. Chemistry 12 (2006) 1216-1220
4. van Vugt-Lussenburg B.M., et al. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. Biochem. Biophys. Res. Commun. 346 (2006) 810-818
5. Lussenburg B.M., et al. Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants. Anal. Biochem. 341 (2005) 148-155
6. Munro A.W., et al. P450 BM3: the very model of a modern flavocytochrome. Trends Biochem. Sci. 27 (2002) 250-257
7. Eiben S., et al. Preparative use of isolated CYP102 monooxygenases: a critical appraisal. J. Biotechnol. 124 (2006) 662-669
8. Hollmann F., et al. Non-enzymatic regeneration of nicotinamide and flavin cofactors for monooxygenase catalysis. Trends Biotechnol. 24 (2006) 163-171
9. Urlacher V.B., and Eiben S. Cytochrome P450 monooxygenases: perspectives for synthetic application. Trends Biotechnol. 24 (2006) 324-330
10. Di Nardo G., et al. Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J. Biol. Inorg. Chem. 12 (2007) 313-323
11. Guengerich F.P. Cytochromes P450, drugs and diseases. Mol. Interv. 3 (2003) 194-204
12. Jiang Y., et al. Radical intermediates in the catalytic oxidation of hydrocarbons by bacterial and human cytochrome P450 enzymes. Biochemistry 45 (2006) 533-542
13. Otey C.R., et al. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnol. Bioeng. 93 (2006) 494-499
14. Vugt-Lussenburg B.M., et al. Identification of critical residues in novel drug-metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J. Med. Chem. 50 (2007) 455-461
15. Landwehr M., et al. Enantioselective α-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J. Am. Chem. Soc. 128 (2006) 6058-6059
16. Otey C.R., et al. Functional evolution and structural conservation in chimeric cytochromes p450: calibrating a structure-guided approach. Chem. Biol. 11 (2004) 309-318
17. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14 (2001) 611-650
18. Peters M.W., et al. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. J. Am. Chem. Soc. 125 (2003) 13442-13450
19. Vail R.B., et al. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J. Ind. Microbiol. Biotechnol. 32 (2005) 67-74
20. Rushmore T.H., et al. Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab. Eng. 2 (2000) 115-125
21. Schaefer W.H., et al. Characterization of the enzymatic and nonenzymatic peroxidative degradation of iron porphyrins and cytochrome P-450 heme. Biochemistry 24 (1985) 3254-3263
22. Zhu M., et al. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos. 33 (2005) 500-507
23. Kim D., et al. Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J. Biol. Chem. 280 (2005) 40319-40327
24. Urlacher V.B., and Schmid R.D. Recent advances in oxygenase-catalyzed biotransformations. Curr. Opin. Chem. Biol. 10 (2006) 156-161
25. Rui L., et al. Protein engineering of toluene ortho-monooxygenase of Burkholderia cepacia G4 for regiospecific hydroxylation of indole to form various indigoid compounds. Appl. Microbiol. Biotechnol. 66 (2005) 422-429
26. Szewczyk R., et al. Application of microscopic fungi isolated from polluted industrial areas for polycyclic aromatic hydrocarbons and pentachlorophenol reduction. Biodegradation 14 (2003) 1-8
27. Berry A., et al. Application of metabolic engineering to improve both the production and use of biotech indigo. J. Ind. Microbiol. Biotechnol. 28 (2002) 127-133
28. Harford-Cross C.F., et al. Protein engineering of cytochrome p450(cam) (CYP101) for the oxidation of polycyclic aromatic hydrocarbons. Protein Eng. 13 (2000) 121-128
29. Ost T.W., et al. Rational re-design of the substrate-binding site of flavocytochrome P450 BM3. FEBS Lett. 486 (2000) 173-177
30. Li Q.S., et al. Rational evolution of a medium chain-specific cytochrome P450 BM-3 variant. Biochim. Biophys. Acta 1545 (2001) 114-121
31. Gilardi G., et al. Molecular Lego: design of molecular assemblies of P450 enzymes for nanobiotechnology. Biosens. Bioelectron. 17 (2002) 133-145
32. Park H.S., et al. Design and evolution of new catalytic activity with an existing protein scaffold. Science 311 (2006) 535-538
33. Guerois R., et al. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 320 (2002) 369-387
34. Wernerus H., and Stahl S. Biotechnological applications for surface-engineered bacteria. Biotechnol. Appl. Biochem. 40 (2004) 209-228
35. Li H., and Poulos T.L. The structure of the cytochrome P450 BM-3 haem domain complexed with the fatty acid substrate palmitoleic acid. Nat. Struct. Biol. 4 (1997) 140-146
36. Ravichandran K.G., et al. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450s. Science 261 (1993) 731-736
37. Alcalde M., et al. Colorimetric high-throughput assay for alkene epoxidation catalyzed by cytochrome P450 BM-3 variant. J. Biomol. Screen. 9 (2004) 141-146
38. Li Q.S., et al. Directed evolution of the fatty-acid hydroxylase P450 BM-3 into an indole-hydroxylating catalyst. Chemistry 6 (2000) 1531-1536
39. Li Q.S., et al. Engineering cytochrome P450 BM-3 for oxidation of polycyclic aromatic hydrocarbons. Appl. Environ. Microbiol. 67 (2001) 5735-5739
40. Sulistyaningdyah W.T., et al. Metabolism of polychlorinated dibenzo-p-dioxins by cytochrome P450 BM-3 and its mutant. Biotechnol. Lett. 26 (2004) 1857-1860
41. Urlacher V., and Schmid R.D. Biotransformations using prokaryotic P450 monooxygenases. Curr. Opin. Biotechnol. 13 (2002) 557-564
42. 5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Biochem. Pharmacol. 52 (1996) 301-309
43. Spatzenegger M., et al. Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling. J. Pharmacol. Exp. Ther. 304 (2003) 477-487
44. Hiroi T., et al. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab. Dispos. 30 (2002) 970-976
45. Li X.Q., et al. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high-affinity and -turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300 (2002) 399-407
46. Lussenburg B.M., et al. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. Biochem. Pharmacol. 70 (2005) 1253-1261
47. 5 by mass spectrometry and site-directed mutagenesis. J. Biol. Chem. 281 (2006) 20404-20417
48. Thummel K.E., et al. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem. Pharmacol. 45 (1993) 1563-1569
49. Keizers P.H., et al. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation. J. Med. Chem. 48 (2005) 6117-6127
50. Asikainen A., et al. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol. In Vitro 17 (2003) 449-455
51. Estavillo C., et al. Epoxidation of styrene by human cyt P450 1A2 by thin film electrolysis and peroxide activation compared to solution reactions. Biophys. Chem. 104 (2003) 291-296
52. Nakajima T., et al. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem. Res. Toxicol. 7 (1994) 891-896
53. Chiappe C., et al. Stereochemistry of the biotransformation of 1-hexene and 2-methyl-1-hexene with rat liver microsomes and purified P450s of rats and humans. Chem. Res. Toxicol. 11 (1998) 1487-1493
54. Gillam E.M., et al. Formation of indigo by recombinant mammalian cytochrome P450. Biochem. Biophys. Res. Commun. 265 (1999) 469-472